Literature DB >> 55833

Letter: Levamisole and bone-marrow restoration after chemotherapy.

J C Lods, P Dujardin, G M Halpern.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 55833     DOI： 10.1016/s0140-6736(76)90351-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Use of levamisole in cancer patients.

Authors:  F Spreafico
Journal:  Drugs       Date:  1980-08       Impact factor: 9.546

2.  Outcome of a novel immunosuppressive strategy of cyclosporine, levamisole and danazol for severe aplastic anemia.

Authors:  Min Wang; Xingxin Li; Jun Shi; Yingqi Shao; Meili Ge; Jinbo Huang; Zhendong Huang; Jing Zhang; Neng Nie; Yizhou Zheng
Journal:  Int J Hematol       Date:  2015-06-14       Impact factor: 2.490

3.  Levamisole Suppresses CD4+ T-Cell Proliferation and Antigen-Presenting Cell Activation in Aplastic Anemia by Regulating the JAK/STAT and TLR Signaling Pathways.

Authors:  Jiali Wang; Jia Liu; Mingyang Wang; Fei Zhao; Meili Ge; Li Liu; Erlie Jiang; Sizhou Feng; Mingzhe Han; Xiaolei Pei; Yizhou Zheng
Journal:  Front Immunol       Date:  2022-07-14       Impact factor: 8.786

4.  Levamisole: evidence for activity on human haemopoietic progenitor cells.

Authors:  J S Senn; C C Lai; G B Price
Journal:  Br J Cancer       Date:  1980-01       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.